-
1Academic Journal
Πηγή: Вопросы обеспечения качества лекарственных средств. :4-10
Θεματικοί όροι: УФ-спектрофотометрия, оценка качества, противоопухолевые средства, валидация, производные 2-аминопиррола, 3. Good health
-
2Academic Journal
Συγγραφείς: A. V. Sultanbaev, K. V. Menshikov, Sh. I. Musin, I. A. Menshikova, N. I. Sultanbaeva, E. V. Popova, V. E. Askarov, А. В. Султанбаев, К. В. Меньшиков, Ш. И. Мусин, И. А. Меньшикова, Н. И. Султанбаева, Е. В. Попова, В. Е. Аскаров
Πηγή: Creative surgery and oncology; Том 13, № 1 (2023); 77-86 ; Креативная хирургия и онкология; Том 13, № 1 (2023); 77-86 ; 2076-3093 ; 2307-0501
Θεματικοί όροι: галихондрин, metastases, eribulin, microtubule inhibitor, anticancer agents, chemotherapy, halichondrin, метастазы, эрибулин, ингибитор микротрубочек, противоопухолевые средства, химиотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.surgonco.ru/jour/article/view/774/540; National Cancer Institute. SEER Cancer Statistics Factsheets: female breast cancer. [cited 2022 Oct 21]. Available from: http://seer.cancer.gov/statfacts/html/breast.html; Kawano S., Ito K., Yahata K., Kira K., Abe T., Akagi T., et al. A landmark in drug discovery based on complex natural product synthesis. Sci Rep. 2019;9(1):8656. DOI:10.1038/s41598-019-45001-9; Dybdal-Hargreaves N.F., Risinger A.L., Mooberry S.L. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015;21(11):2445–52. DOI:10.1158/1078-0432. CCR-14-3252; Halaven (eribulin mesylate) injection, for intravenous use [prescribing information]. Eisai Inc., 2016.; Wang X., Liu S., Xue Y. Treatment strategy and safety of Eribulin in advanced breast cancer. J Coll Physicians Surg Pak. 2022;32(1):122–4. DOI:10.29271/jcpsp.2022.01.122. PMID: 34983165; O'Shaughnessy J., Kaklamani V., Kalinsky K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncol. 2019;15(14):1641–53. DOI:10.2217/fon2018-0936; Halaven 0.44 mg/ml solution for injection [summary of product characteristics]. Hertfordshire: Eisai Europe Limited; 2017.; Pedersini R., di Mauro P., Amoroso V., Parati M.C., Turla A., Ghilardi M., et al. Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data. J Geriatr Oncol. 2020;11(6):976–81. DOI:10.1016/j.jgo.2020.03.021; López González A., Del Barco Berrón S., Grau I., Galan M., Castelo Fernández B., Cortés A., et al. Challenging endocrine sensitivity of hormone receptor-positive/HER2-negative advanced breast cancer with the combination of eribulin and endocrine therapy: the REVERT study. Cancers (Basel). 2022;14(23):5880. DOI:10.3390/cancers14235880; Pellegrino B., Cavanna L., Boggiani D., Zamagni C., Frassoldati A., Schirone A., et al. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO Open. 2021;6(1):100019. DOI:10.1016/j.esmoop.2020.100019; Olatunde O.Z., Yong J., Lu C. The progress of the anticancer agents related to the microtubules target. Mini Rev Med Chem. 2020;20(20):2165–92. DOI:10.2174/1389557520666200729162510; Okouneva T., Azarenko O., Wilson L., Littlefield B.A., Jordan M.A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 2008;7(7):2003–11. DOI:10.1158/15357163.MCT-08-0095; Smith J.A., Wilson L., Azarenko O., Zhu X., Lewis B.M., Littlefield B.A., et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49(6):1331–7. DOI:10.1021/bi901810u; Kenny L., Beresford M., Brown I., Misra V., Kristeleit H. Eribulin for the treatment of advanced breast cancer: A prospective observational registry study. Eur J Cancer Care (Engl). 2022;31(6):e13747. DOI:10.1111/ecc.13747; Kashiwagi S., Asano Y., Goto W., Takada K., Morisaki T., Kouhashi R., et al. Validation of systemic and local tumour immune response to eribulin chemotherapy in the treatment of breast cancer. Anticancer Res. 2020;40(6):3345–54. DOI:10.21873/anticanres.14317; Uemura D., Takahashi K., Yamamoto T., Katayama C., Tanaka J., Okumura Y., et al. Norhalichondrin A: An antitumor polyether macrolide from a marine sponge. J Am Chem Soc. 1985;107(16):4796–8. DOI:10.1021/ja00302a042; Swami U., Chaudhary I., Ghalib M.H., Goel S. Eribulin — A review of preclinical and clinical studies. Crit Rev Oncol Hematol. 2012;81(2):163–84. DOI:10.1016/j.critrevonc.2011.03.002; Donoghue M., Lemery S.J., Yuan W., He K., Sridhara R., Shord S., et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: Use of a “physician’s choice” control arm in a randomized approval trial. Clin Cancer Res. 2012;18(6):1496–505. DOI:10.1158/1078-0432.CCR-11-2149.; Jordan M.A., Kamath K., Manna T., Okouneva T., Miller H.P., Davis C., et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4(7):1086–95. DOI:10.1158/1535-7163.MCT-04-0345; Tan A.R., Rubin E.H., Walton D.C., Shuster D.E., Wong Y.N., Fang F., et al. Phase I study of eribulin mesylate administered once every days in patients with advanced solid tumors. Clin Cancer Res. 2009;15(12):4213–9. DOI:10.1158/1078-0432.CCR-09-0360; de Nonneville A., Sabatier R., Gonçalves A., Extra J.M., Tarpin C., Launay S., et al. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer. J Geriatr Oncol. 2018;9(3):281–3. DOI:10.1016/j.jgo.2017.11.003; Fukada I., Ito Y., Kondo N., Ohtani S., Hattori M., Tokunaga E., et al. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). Breast Cancer Res Treat. 2021;190(3):425– 34. DOI:10.1007/s10549-021-06396-0; Towle M.J., Salvato K.A., Budrow J., Wels B.F., Kuznetsov G., Aalfs K.K., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013– 21. PMID: 11221827; Aogi K., Iwata H., Masuda N., Mukai H., Yoshida M., Rai Y., et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012;23(6):1441–8. DOI:10.1093/ annonc/mdr444; Cortes J., Vahdat L., Blum J.L., Twelves C., Campone M., Roché H., et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously reated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28(25):3922–8. DOI:10.1200/JCO.2009.25.8467; Vahdat L.T., Pruitt B., Fabian C.J., Rivera R.R., Smith D.A., Tan-Chiu E., et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27(18):2954–61. DOI:10.1200/JCO.2008.17.7618; Cortes J., O'Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23. DOI:10.1016/S0140-6736(11)60070-6; Twelves C., Cortes J., Vahdat L.T., Wanders J., Akerele C., Kaufman P.A. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010;10(2):160–3. DOI:10.3816/CBC.2010.n.023; Greenhalgh J., Bagust A., Boland A., Oyee J., Trevor N., Beale S., et al. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal. Pharmacoeconomics. 2015;33(2):137–48. DOI:10.1007/s40273-014-0214-2; Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G., et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601. DOI:10.1200/JCO.2013.52.4892; Manso L., Moreno Antón F., Izarzugaza Perón Y., Delgado Mingorance J.I., Borrega García P., Echarri González M.J., et al. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J. 2019;25(2):219–25. DOI:10.1111/tbj.13199; Sang D., Song L.H., Di L.J., Wang Y.L., Liu C.G., Guo Z.Q., et al. Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer. Zhonghua Zhong Liu Za Zhi. 2022;44(4):364–9. DOI:10.3760/cma.j.cn112152-20210226-00173; Hayashida T., Jinno H., Mori K., Sato H., Matsui A., Sakurai T., et al. Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: a multicenter, singlearm trial. BMC Cancer. 2018;18(1):701. DOI:10.1186/s12885-0184628-7; Yamashita T., Kawaguchi H., Masuda N., Kitada M., Narui K., Hattori M., et al. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). Invest New Drugs. 2021;39(1):217–25. DOI:10.1007/s10637-020-00991-6; De Angelis C., Bruzzese D., Bernardo A., Baldini E., Leo L., Fabi A., et al. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open. 2021;6(2):100097. DOI:10.1016/j.esmoop.2021.100054; National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Female Breast Cancer Subtypes. [cited 2020 June 4]. Available from: https://seer.cancer.gov/statfacts/html/breastsubtypes.html; Mougalian S.S., Kish J.K., Zhang J., Liassou D., Feinberg B.A. Effectiveness of eribulin in metastatic breast cancer: 10 years of real-world clinical experience in the United States. Adv Ther. 2021;38(5):2213–25. DOI:10.1007/s12325-020-01613-6; Филоненко Д.В., Белоногов А.В. Опыт применения эрибулина в условиях реальной клинической практики. Злокачественные опухоли. 2017;7(4):21–8. DOI:10.18027/2224-5057-2017-7-4-21-28; Watanabe J., Ito Y., Ohsumi S., Mizutani M., Tashiro H., Sakurai K., et al. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing ob-servational study. Investig New Drugs. 2017;35:791–9. DOI:10.1007/s10637-0170486-4; Maeda S., Saimura M., Minami S., Kurashita K., Nishimura R., Kai Y., et al. Efficacy and safety of eribulin as firstto third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Breast. 2017;32:66–72. DOI:10.1016/j.breast.2016.12.017; Chen P.H., Yeh D.C., Tung H.H., Lin C.Y. Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer. Medicine (Baltimore). 2021;100(47):e27859. DOI:10.1097/ MD.0000000000027859; Pivot X., Im S.A., Guo M., Marmé F. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer. 2018;25(3):370–4. DOI:10.1007/s12282017-0826-4; Inoue K., Saito T., Okubo K., Kimizuka K., Yamada H., Sakurai T., et al. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance. Breast Cancer Res Treat. 2016;157:295–305. DOI:10.1007/ s10549-016-3808-x; Watanabe J. Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. Springerplus. 2015;4:625. DOI:10.1186/ s40064-015-1422-8; Kikuchi Y., Uchida Y., Shirakawa K., Kanauchi H., Niwa T., Nishioka K., et al. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens. Asia Pac J Clin Oncol. 2018;14:e231–7. DOI:10.1111/ajco.12863; Inoue K., Takahashi M., Mukai H., Yamanaka T., Egawa C., Sakata Y., et al. Effectiveness and safety of eribulin in Japanese patients with HER2negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Invest New Drugs. 2020;38(5):1540–9. DOI:10.1007/s10637-019-00890-5; https://www.surgonco.ru/jour/article/view/774
-
3Academic Journal
Συγγραφείς: Palko, N.N., Potemkin, V.A., Grishina, M.A.
Πηγή: Bulletin of the South Ural State University series "Chemistry". 11:18-24
Θεματικοί όροι: УДК 544.165, decision trees, structural 3D descriptors, структурные 3D дескрипторы, механизм действия, противоопухолевые средства, классифицирующее правило, antitumor drugs, 01 natural sciences, mechanism of action, 0104 chemical sciences
Περιγραφή αρχείου: application/pdf
-
4Academic Journal
Πηγή: Лекарства Украины; № 2-3(258-259) (2022); 37-40
Medicine of Ukraine; No. 2-3(258-259) (2022); 37-40
Ліки України; № 2-3(258-259) (2022); 37-40Θεματικοί όροι: 2. Zero hunger, антибактеріальні засоби, грибы, противоопухолевые средства, endophytes, 3. Good health, протипухлинні засоби, эндофиты, бактерії, гриби, ендофіти, Anti-bacterial agents, антибактериальные средства, antineoplastic agents, бактерии, fungi, bacteria
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/264060
-
5Academic Journal
Συγγραφείς: O. D. Ostroumova, I. V. Goloborodova, О. Д. Остроумова, И. В. Голобородова
Συνεισφορές: Работа выполнена без спонсорской поддержки.
Πηγή: Safety and Risk of Pharmacotherapy; Том 8, № 1 (2020); 23-35 ; Безопасность и риск фармакотерапии; Том 8, № 1 (2020); 23-35 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2020-8-1
Θεματικοί όροι: нестероидные противовоспалительные средства, drug-induced heart failure, calcium channel blockers, beta-blockers, antiarrhythmics, hypoglycemic drugs, anthracyclines, anticancer drugs, non-steroidal anti-infl ammatory drugs, лекарственно-индуцированная сердечная недостаточность, блокаторы кальциевых каналов, бета-блокаторы, антиаритмические препараты, гипогликемические препараты, антрациклины, противоопухолевые средства
Περιγραφή αρχείου: application/pdf
Relation: https://www.risksafety.ru/jour/article/view/171/231; Мареев ВЮ, Фомин ИВ, Агеев ФТ, Беграмбекова ЮЛ, Васюк ЮА, Гарганеева АА и др. Клинические рекомендации ОССН — РКО — РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8–158.; Гарганеева АА, Бауэр ВА, Борель КН. Пандемия XXI века: хроническая сердечная недостаточность — бремя современного общества. Эпидемиологические аспекты (обзор литературы). Сибирский медицинский журнал. 2014;29(3):8–12.; Page RL 2nd, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. Drugs that may cause or exacerbate heart failure: a scientifi c statement from the American Heart Association. Circulation. 2016;134(6):е32–69. https://doi.org/10.1161/CIR.0000000000000426; Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. https://doi.org/10.1093/eurheartj/ehw128; Al Hamarneh YN, Tsuyuki RT. Heart failure. In: Tisdale JE, Miller DA, eds. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda: American Society of Health-System Pharmacists; 2018. Р. 501–21.; DeFrances CJ, Cullen KA, Kozak LJ. National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2007;13(165).; Беленков ЮН, Мереев ВЮ, Агеев ФТ, Фомин ИВ, Бадин ЮВ, Поляков ДС и др. Современный образ пациента с ХСН в европейской части Российской Федерации (госпитальный этап). Сердечная недостаточность. 2011;12(5):255–9.; Ситникова МЮ, Лясникова ЕА, Трукшина МА. Хроническая сердечная недостаточность: эпидемиология и перспективы планирования. Журнал Сердечная недостаточность. 2012;13(6):372–6.; Напалков ДА, Сулимов ВА, Сеидов НМ. Хроническая сердечная недостаточность: смещение фокуса на начальные стадии заболевания. Лечащий врач. 2008;8(4):58–60; Parkes JD, Marsden CD, Price P. Amantadine-induced heartfailure. Lancet. 1977;309(8017):904. https://doi.org/10.1016/s0140-6736(77)91226-0; Maxwell CB, Jenkins АT. Drug-induced heart failure. Am J Health Syst Pharm. 2011;68(19):1791–804. https://doi.org/10.2146/ajhp100637; Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 2003;41(8):1394–8. https://doi.org/10.1016/S0735-1097(03)00159-1; Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427– 43. https://doi.org/10.1056/NEJMoa066224; The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368(9541):1096–105. https://doi.org/10.1016/S0140-6736(06)69420-8; Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis. N Engl J Med. 2007;357(1):28–38. https://doi.org/10.1056/NEJMoa073394; Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89. https://doi.org/10.1016/s0140-6736(05)67528-9; Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11(2):115–28. https://doi.org/10.2165/11587580-000000000-00000; Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf. 2011;20(8):785–96. https://doi.org/10.1002/pds.2165; Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011;342:d1309. https://doi.org/10.1136/bmj.d1309; Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet. 2007;370(9593):1129–36. https://doi.org/10.1016/S0140-6736(07)61514-1; Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304(4):411– 8. https://doi.org/10.1001/jama.2010.920; Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88. https://doi.org/10.1161/circulationaha.114.010389; White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. https://doi.org/10.1056/NEJMoa1305889; Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. https://doi.org/10.1056/NEJMoa1501352; Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710– 7. https://doi.org/10.7326/0003-4819-91-5-710; Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–79. https://doi.org/10.1002/cncr.11407; Kremer LC, van Dalen EC, Offringa M, Voûte PA, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13(4):503–12. https://doi.org/10.1093/annonc/mdf118; Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. https://doi.org/10.1056/NEJM200103153441101; Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008;31(6):459–67. https://doi.org/10.2165/00002018200831060-00002; Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84. https://doi.org/10.1056/NEJMoa052122; Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-assоciated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25(25):3859–65. https://doi.org/10.1200/JCO.2006.09.1611; Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–9. https://doi.org/10.1200/JCO.2005.02.4091; Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72. https://doi.org/10.1056/NEJMoa052306; Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809–20. https://doi.org/10.1056/NEJMoa053028; Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21. https://doi.org/10.1200/JCO.2002.20.5.1215; Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24(25):4107–15. https://doi.org/10.1200/JCO.2005.04.9551; Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29(6):632– 8. https://doi.org/10.1200/JCO.2010.31.9129; Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infl iximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–40. https://doi.org/10.1161/01.CIR.0000077913.60364.D2; Ravid S, Podrid PJ, Lampert S, Lown B. Congestive heart failure induced by six of the newer antiarrhythmic drugs. J Am Coll Cardiol. 1989;14(5):1326–30. https://doi.org/10.1016/0735-1097(89)90436-1; Greene HL, Richardson DW, Hallstrom AP, McBride R, Capone RJ, Barker AH, et al. Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). Am J Cardiol. 1989;63(7):393–8. https://doi.org/10.1016/0002-9149(89)90306-8; Pfi sterer M. Negative inotropic effects of antiarrhythmic drugs: a clinical point of view. J Cardiovasc Pharmacol. 1991;17(Suppl 6):S44–7.; Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68(13):1476–88. https://doi.org/10.1016/j.jacc.2016.05.011; Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crij ns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678–87. https://doi.org/10.1056/NEJMoa0800456; Hohnloser SH, Crij ns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668–78. https://doi.org/10.1056/NEJMoa0803778; Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. https://doi.org/10.1093/eurheartj/ehw210; The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319(7):385–92. https://doi.org/10.1056/NEJM198808183190701; Moss AJ, Oakes D, Benhorin J, Carleen E. The interaction between diltiazem and left ventricular function after myocardial infarction. Multicenter Diltiazem Post-Infarction Research Group. Circulation. 1989;80(Suppl 6):IV102–6.; Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83(1):52–60. https://doi.org/10.1161/01.cir.83.1.52; Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82(6):1954–61. https://doi.org/10.1161/01.cir.82.6.1954; Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O’Connor C, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (Prospective Randomized Amlodipine Survival Evaluation 2). JACC Heart Fail. 2013;1(4):308–14. https://doi.org/10.1016/j.jchf.2013.04.004; Greenblatt DJ, Koch-Weser J. Adverse reactions to β-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs. 1974;7(1-2):118–29. https://doi.org/10.2165/00003495-197407010-00008; McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cariovascular Society heart failure management guideline update: focus on acute and chronic heart failure. Can J Cardiol. 2013;29(2):168–81. https://doi.org/10.1016/j.cjca.2012.10.007; Tsuyuki RT, McAlister FA, Teo KK. β-blockers for congestive heart failure: what is the current consensus? Drugs Aging. 2000;16(1):1–7. https://doi.org/10.2165/00002512-200016010-00001; Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of β-adrenergic blockade in chronic heart failure: a metaanalysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98(12):1184–91. https://doi.org/10.1161/01.cir.98.12.1184; Avezum A, Tsuyuki RT, Pogue J, Yusuf S. Beta-blocker therapy for congestive heart failure: a systemic overview and critical appraisal of the published trials. Can J Cardiol. 1998;14(8):1045–53.; Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz HM. Adverse effects of β-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med. 2004;164(13):1389–94. https://doi.org/10.1001/archinte.164.13.1389; Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Ann Intern Med. 1990;112(2):120–5. https://doi.org/10.7326/0003-4819-112-2-120; Munroe WP, Rindone JP, Kershner RM. Systemic side effects associated with the ophthalmic administration of timolol. Drug Intell Clin Pharm. 1985;19(2):85–9. https://doi.org/10.1177/106002808501900201; Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158(10):1108–12. https://doi.org/10.1001/archinte.158.10.1108; Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-infl ammatory drugs and heart failure. Drugs. 2003;63(6):525–34. https://doi.org/10.2165/00003495200363060-00001; Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Cost of heart failure among hypertensive users of nonspecifi c NSAIDs and COX-2-specific inhibitors. Am J Manag Care. 2002;8(15 Suppl):S414–27.; Whelton A, White WB, Bello AE, Puma JA, Fort JG, SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90(9):959–63. https://doi.org/10.1016/s0002-9149(02)02661-9; Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-infl ammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363(9423):1751–6. https://doi.org/10.1016/S0140-6736(04)16299-5; Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal antiinfl ammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141–9. https://doi.org/10.1001/archinternmed.2008.525; https://www.risksafety.ru/jour/article/view/171
-
6Academic Journal
Συγγραφείς: K. S. Gumerova, G. M. Sakhautdinova, I. M. Polyakova, К. С. Гумерова, Г. М. Сахаутдинова, И. М. Полякова
Πηγή: Creative surgery and oncology; Том 9, № 4 (2019); 285-292 ; Креативная хирургия и онкология; Том 9, № 4 (2019); 285-292 ; 2076-3093 ; 2307-0501 ; 10.24060/2076-3093-2019-9-4
Θεματικοί όροι: CRISPR-ассоциированный белок 9, cancer, antineoplastic agents, cardiotoxicity, anthracyclines, receptor ErbB-2, immunotherapy, proteasome inhibitors, CRISPR-Associated Protein 9, рак, противоопухолевые средства, кардиотоксичность, антрациклины, рецепторы ErbB-2, иммунотерапия, ингибиторы протеасом
Περιγραφή αρχείου: application/pdf
Relation: https://www.surgonco.ru/jour/article/view/436/368; U.S. National Library of Medicine: National Institutes of Health; 2018. Available from: https://www.nih.gov; Cheungpasitporn W., Kopecky S.L., Specks U., Bharucha K., Fervenza F.C. Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. J Renal Inj Prev. 2017;6(1):18–25. DOI:10.15171/jrip.2017.04; Dong J., Chen H. Cardiotoxicity of anticancer therapeutics. Front Cardiovasc Med. 2018;5:9. DOI:10.3389/fcvm.2018.00009; Меморандум ESC по лечению онкологических заболеваний и сердечно-сосудистой токсичности, разработанный под эгидой комитета по практике ESC 2016. Российский кардиологический журнал. 2017;22(3):105–39. DOI:10.15829/1560-4071-2017-3-105139; Сакаева Д.Д. Алгоритмы ведения пациентов с нежелательными явлениями на фоне терапии ингибиторами тирозинкиназы. Медицинский совет. 2017;(6):38–50. DOI:10.21518/2079-701X2017-6-38-50; Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(9):547–58. DOI:10.1038/nrcardio.2015.65; Brana I., Zamora E., Oristrell G., Tabernero J. Side effects of medical cancer therapy. Cardiotoxicity. 2018;14:406. DOI:10.1007/978-3-31970253-7_14; Shah C., Gong Y., Szady A., Sun Q., Pepine C.J., Langaee T., et al. Unanticipated cardiotoxicity associated with targeted anticancer therapy in patients with hematologic malignancies patients: natural history and risk factors. Cardiovasc Toxicol. 2018;18(2):184–91. DOI:10.1007/s12012-017-9429-8; Heinzerling L., Ott P.A., Hodi F.S., Husain A.N., Tajmir-Riahi A., Tawbi H., et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50. DOI:10.1186/s40425-016-0152-y; Pugazhendhi A., Edison T.N.J., Velmurugan B.K., Jacob J.A., Karuppusamy I. Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci. 2018;200:26–30. DOI:10.1016/j.lfs.2018.03.023; Raschi E., Diemberger I., Cosmi B., De Ponti F. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authors’ reply. Intern Emerg Med. 2018;13(4):635–6. DOI:10.1007/s11739-018-1853-7; Ghosh A.K., Walker J.M. Cardio-oncology. Br J Hosp Med (Lond). 2017;78(1):C11–3. DOI:10.12968/hmed.2017.78.1.C11; Feijen E.A.M., Leisenring W.M., Stratton K.L., Ness K.K., van der Pal H.J.H., van Dalen E.C., et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol. 2019;5(6):864–71. DOI:10.1001/jamaoncol.2018.6634; Shah C.P., Moreb J.S. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Ther Adv Cardiovasc Dis. 2019;13:1753944719843435. DOI:10.1177/175394471984343; Снеговая А.В., Виценя М.В., Копп М.В., Ларионова В.Б. Практические рекомендации по коррекции кардиоваскулярной токсичности, индуцированной химиотерапией и таргетными препаратами. Злокачественные опухоли. 2016;(4-S2):418–27. DOI:10.18027/2224-5057-2016-4s2-418-427; Henriksen P.A. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971–7. DOI:10.1136/heartjnl-2017-312103; Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., Aboyans V., Asteggiano R., Galderisi M., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801. DOI:10.1093/eurheartj/ehw211; Di Lisi D., Madonna R., Zito C., Bronte E., Badalamenti G., Parrella P., et al. Anticancer therapy-induced vascular toxicity. VEGF inhibition and beyond. Int J Cardiol. 2017;227:11–7. DOI:10.1016/j.ijcard.2016.11.174; Голубцов О.Ю., Тыренко В.В., Лютов В.В., Масляков В.В., Макиев Р.Г. Кардиоваскулярные осложнения противоопухолевой терапии. Современные проблемы науки и образования. 2017;22(2):126.; Habibi H.R. The complex picture of new therapeutic modalities and their potential cardiovascular effects, “Cardio-oncology challenge extends to other field of medicine”. J Cardiovasc Dis Card Surg. 2018:07–09. DOI: https://doi.org/10.29199/CDCS.101013; Tromp J., Steggink L.C., Van Veldhuisen D.J., Gietema J.A., van der Meer P. Cardio-oncology. Progress in diagnosis and treatment of cardiac dysfunction. Clin Pharmacol Ther. 2017;101(4):481–90. DOI:10.1002/cpt.614; Zheng P.P., Li J., Kros J.M. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: critical research-practice gaps, challenges, and insights. Med Res Rev. 2018;38(1):325–76. DOI:10.1002/med.21463; Cuomo A., Rodolico A., Galdieri A., Russo M., Campi G., Franco R., et al. Heart failure and cancer: mechanisms of old and new cardiotoxic drugs in cancer patients. Card Fail Rev. 2019;5(2):112–8. DOI:10.15420/cfr.2018.32.2; Jain D., Ahmad T., Cairo M., Aronow W. Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment. Ann Transl Med. 2017;5(17):348. DOI:10.21037/atm.2017.06.35; Яндиева Р.А., Сарибекян Э.К., Мамедов М.Н. Кардиотоксичность при лечении онкологических заболеваний. Международный журнал сердца и сосудистых заболеваний. 2018;6(17):3–11.; Lenneman C.G., Sawyer D.B. An update on cardiotoxicity of cancerrelated treatment. Circ Res. 2016:118(6):1008–20. DOI:10.1161/CIRCRESAHA.115.303633; Wittayanukorn S., Qian J., Westrick S.C., Billor N., Johnson B., Hansen R.A. Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or beta-blockers in older adults with breast cancer. Am J Clin Oncol. 2018;41(9):909–18. DOI:10.1097/COC.0000000000000389; Hrynchak I., Sousa E., Pinto M., Costa V.M. The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs. Drug Metab Rev. 2017;49(2):158–96. DOI:10.1080/03602532.2017.1316285; Avelar E., Strickland C.R., Rosito G. Role of imaging in cardio-oncology. Curr Treat Options Cardiovasc Med. 2017;19:46. DOI:10.1007/s11936-017-0546-2; McGowan J.V., Chung R., Maulik A., Piotrowska I., Walker J.M., Yellon D. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31:63–75. DOI:10.1007/s10557-016-6711-0; Wilkinson E.L., Sidaway J.E., Cross M.J. Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability. Biol Open. 2016;5(10):1362–70. DOI:10.1242/bio.020362; Curigliano G., Cardinale D., Dent S., Criscitiello C., Aseyev O., Lenihan D., et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309–25. DOI:10.3322/caac.21341; Abdel-Qadir H., Ethier J.L., Lee D.S., Thavendiranathan P., Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120–7. DOI:10.1016/j.ctrv.2016.12.002; Tromp J., Steggink L.C., Van Veldhuisen D.J., Gietema J.A., van der Meer P. Cardio-oncology: progress in diagnosis and treatment of cardiac dysfunction. Clin Pharmacol Ther. 2017;101:481–90. DOI:10.1002/cpt.614; Chen Z.I., Ai D.I. Cardiotoxicity associated with targeted cancer therapies. Mol Clin Oncol. 2016;4:675–81. DOI:10.3892/mco.2016.800; Walls G.M., Lyon A.R., Harbinson M.T., Hanna G.G. Cardiotoxicity following cancer treatment. Ulster Med J. 2017;86(1):3–9. PMID: 28298705; De Angelis A., Urbanek K., Cappetta D., Piegari E., Pia Ciuffreda L., Rivellino A., et al. Doxorubicin cardiotoxicity and target cells: a broader perspective. Cardiooncology. 2016;2:2. DOI:10.1186/s40959016-0012-4; Tahover E., Segal A., Isacson R., Rosengarten O., Grenader T., Gips M., et al. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival. Anticancer Drugs. 2017;28:787–94. DOI:10.1097/CAD.0000000000000514; Coen van Hassselt J.G., Iyengar R. Systems pharmacology-based identification of pharmacogenomic determinants of adverse drug reactions using human iPSC-derived cell lines. Curr Opin Syst Biol. 2017;4:9–15. DOI:10.1016/j.coisb.2017.05.006; https://www.surgonco.ru/jour/article/view/436
-
7Academic Journal
Συγγραφείς: O. A. Beylerli, I. F. Gareev, Sh. Zhao, X. Chen
Πηγή: Креативная хирургия и онкология, Vol 9, Iss 3, Pp 216-222 (2019)
Θεματικοί όροι: глиобластома, центральная нервная система, стволовые клетки, опухолевые стволовые клетки, стволовые клетки глиобластомы, терапевтические мишени, биомаркеры новообразований, сигнальный путь, анкилирующие противоопухолевые средства, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Relation: https://www.surgonco.ru/jour/article/view/419; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/dd057ebe905e4aa98ee232bda4cdee83
-
8Academic Journal
Συγγραφείς: Куликовский, В. Ф., Осипов, П. Г., Хощенко, Ю. А., Ханин, Ю. С., Береш, А. А.
Θεματικοί όροι: медицина, онкология, фармакология, онкоурология, новообразования, опухоли, доброкачественная гиперплазия, аденома предстательной железы, дизурия, послеоперационный период, противоопухолевые средства, антибиотики
Διαθεσιμότητα: http://dspace.bsu.edu.ru/handle/123456789/60580
-
9Academic Journal
Θεματικοί όροι: доброкачественная гиперплазия, фармакология, дизурия, онкология, онкоурология, послеоперационный период, противоопухолевые средства, аденома предстательной железы, опухоли, антибиотики, медицина, новообразования
Σύνδεσμος πρόσβασης: https://openrepository.ru/article?id=11743
-
10Academic Journal
Συγγραφείς: Автина, Т. В., Куликов, А. Л., Покровский, М. В.
Θεματικοί όροι: медицина, фармакология, противоопухолевые средства, иматиниб, плазма крови, жидкостная хроматография, масс-спектрометрический детектор, валидация
Διαθεσιμότητα: http://dspace.bsu.edu.ru/handle/123456789/42704
-
11Academic Journal
ЯДЕРНЫЙ ФАКТОР КАППА В (NF-KB) В КАЧЕСТВЕ МИШЕНИ ДЛЯ ДЕЙСТВИЯ ПРИРОДНЫХ ПРОТИВООПУХОЛЕВЫХ СОЕДИНЕНИЙ
Συγγραφείς: КЛААН НАТАЛЬЯ КОНСТАНТИНОВНА, ПРОНИНА Т.А., АКИНЬШИНА Л.П., РЕШЕТНИКОВА В.В.
Θεματικοί όροι: ЯДЕРНЫЙ ФАКТОР КАППА В (NF-KB), ОПУХОЛИ ЗЛОКАЧЕСТВЕННЫЕ, ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА, NUCLEAR FACTOR KAPPA В
Περιγραφή αρχείου: text/html
-
12Academic Journal
Συγγραφείς: Деннер, В., Епрынцева, Е.
Θεματικοί όροι: КАРОТИНОИДЫ, ШАЛФЕЙ СТЕПНОЙ, КРАПИВА ДВУДОМНАЯ, АНТИОКСИДАНТЫ, АНТИГИПОКСАНТЫ, ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА, ВИТАМИННЫЕ РАСТЕНИЯ
Περιγραφή αρχείου: text/html
-
13Academic Journal
Συγγραφείς: Тарвердян, А.
Θεματικοί όροι: ЛЕКТИНЫ,ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА
Περιγραφή αρχείου: text/html
-
14Academic Journal
Συγγραφείς: Морев, Р., Васильченко, А., Платонов, M., Григоренко, А., Волкова, Е., Зозуля, С.
Περιγραφή αρχείου: text/html
-
15Academic Journal
Συγγραφείς: Усова, Нэлли, Усов, Лев
Θεματικοί όροι: ХЕЙЛИТ, ЭРОЗИЯ, УЗЕЛОК, ГИПЕРКЕРАТОЗ, КРАСНАЯ КАЙМА ГУБ, ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА
Περιγραφή αρχείου: text/html
-
16Academic Journal
Συγγραφείς: Кавалай, Анна
Θεματικοί όροι: ИННОВАЦИОННЫЕ ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА, ОНКОЛОГИЧЕСКИЕ ЗАБОЛЕВАНИЯ, ПАЦИЕНТСКИЕ ОРГАНИЗАЦИИ, ПРОГРАММЫ ГОСГАРАНТИЙ, ПРОГРАММЫ МОДЕРНИЗАЦИИ ЗДРАВООХРАНЕНИЯ, СИСТЕМА ОБЕСПЕЧЕНИЯ ЛЕКАРСТВЕННЫМИ СРЕДСТВАМИ, ФАРМАЦЕВТИЧЕСКАЯ ОТРАСЛЬ, ФАРМАЦЕВТИЧЕСКАЯ ПРОМЫШЛЕННОСТЬ
Περιγραφή αρχείου: text/html
-
17Academic Journal
Συγγραφείς: Дружков, Олег, Гатауллин, Ильгиз, Дружков, Максим
Θεματικοί όροι: РАК МОЛОЧНОЙ ЖЕЛЕЗЫ, ХИМИОТЕРАПИЯ, ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА, ЛОКАЛЬНЫЙ РЕЦИДИВ, ИММУНОФЕНОТИП, ИММУНОГИСТОХИМИЧЕСКАЯ ДИАГНОСТИКА, ПАТОЛОГИЯ ДИФФЕРЕНЦИРОВКИ КЛЕТОК, МАЛИГНИЗАЦИЯ, ОНКОГЕН HER2/NEU, РЕЦЕПТОРЫ ЭСТРОГЕНОВ, РЕЦЕПТОРЫ ПРОГЕСТЕРОНА, HER2/NEU ONCOGENE PROTEIN
Περιγραφή αρχείου: text/html
-
18Academic Journal
Συγγραφείς: Овод, А., Мамаев, А.
Θεματικοί όροι: ОНКОУРОЛОГИЧЕСКИЕ БОЛЬНЫЕ, ХИМИОТЕРАПИЯ, ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА, МАРКЕТИНГОВЫЕ ИССЛЕДОВАНИЯ, ЛЕКАРСТВЕННЫЙ АССОРТИМЕНТ
Περιγραφή αρχείου: text/html
-
19Academic Journal
Συγγραφείς: Арустамова, А. А., Белоус, А. С., Покровский, М. В., Покровская, Т. Г., Якушев, В. И.
Θεματικοί όροι: медицина, фармакология, лекарственные препараты, противоопухолевые средства, авастин, бевацизумаб, эндотелий, оксид азота
Διαθεσιμότητα: http://dspace.bsu.edu.ru/handle/123456789/54083
-
20Academic Journal
Συγγραφείς: Karpenko, Yu. V., Brazhko, O. A., Omelyanchik, L. O.
Πηγή: Актуальні питання фармацевтичної та медичної науки та практики; № 1 (2015)
Current issues in pharmacy and medicine: science and practice; № 1 (2015)
Актуальные вопросы фармацевтической и медицинской науки и практики; № 1 (2015)Θεματικοί όροι: Forecasting, 1,2,4-triazole, Antineoplastic Agents, Anticonvulsants, Structure-Activity Relationship, прогнозування, 1,2,4-тріазол, протипухлинні засоби, антиконвульсанти, залежність «структура-дія», прогнозирование, 1,2,4-триазол, противоопухолевые средства, антиконвульсанты, зависимость «структура-действие»
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://pharmed.zsmu.edu.ua/article/view/41644
